Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry.
Healthcare resource use
Idiopathic pulmonary fibrosis
Mortality
Multivariate analysis
Patient registry
Quality of life
Real world
Univariate analysis
Journal
Pulmonary therapy
ISSN: 2364-1746
Titre abrégé: Pulm Ther
Pays: United States
ID NLM: 101687144
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
21
01
2022
accepted:
21
03
2022
pubmed:
17
4
2022
medline:
17
4
2022
entrez:
16
4
2022
Statut:
ppublish
Résumé
The PROOF registry is a prospective, observational study that aimed to monitor disease progression in a real-world cohort of patients with idiopathic pulmonary fibrosis (IPF). Here, longitudinal quality-of-life (QoL) outcomes, healthcare resource use (HCRU), and the association between QoL and mortality in patients enrolled in the PROOF registry are presented. QoL outcomes (St. George's Respiratory Questionnaire [SGRQ], EuroQoL-5 dimensions-5 levels Health Questionnaire [EQ-5D-5L], EuroQoL-5 dimensions Health Questionnaire [EQ-5D] visual analogue scale [VAS] and cough VAS) and HCRU were collected for all patients. Associations between baseline QoL and mortality were assessed using univariate and multivariate analyses. During multivariate analyses, individual QoL measures were adjusted for the following covariates: age, sex, percent predicted forced vital capacity, percent predicted diffusing capacity of the lungs for carbon monoxide, smoking status, and supplementary oxygen use at registry inclusion. In total, 277 patients were enrolled in the PROOF registry. During the follow-up period, worsening in cough VAS score, SGRQ symptom score, and SGRQ activity score was observed, while EQ-5D VAS, SGRQ total score, and SGRQ impact score remained stable. During univariate analyses, EQ-5D VAS and all SGRQ sub-scores and total score at baseline were associated with mortality; however, during multivariate analyses, only the SGRQ total score, SGRQ impact score, and SGRQ symptom score at baseline were associated with mortality. During the follow-up period, 261 (94.2%) patients required an outpatient consultation (IPF- or non-IPF-related) and there were 182 hospitalizations in total, most of which were respiratory related (66.5%). The PROOF registry provided valuable, real-world data on the association between baseline QoL and mortality, and longitudinal HCRU and QoL outcomes in patients with IPF over 24 months and identified that SGRQ may be an independent prognostic factor in IPF.
Identifiants
pubmed: 35429319
doi: 10.1007/s41030-022-00187-8
pii: 10.1007/s41030-022-00187-8
pmc: PMC9098727
doi:
Types de publication
Journal Article
Langues
eng
Pagination
181-194Informations de copyright
© 2022. The Author(s).
Références
Chest. 2020 May;157(5):1188-1198
pubmed: 31954102
Respirology. 2017 Nov;22(8):1592-1597
pubmed: 28544079
Chest. 2021 Jan;159(1):219-227
pubmed: 32717266
BMC Pulm Med. 2016 Jan 14;16:10
pubmed: 26762154
Eur Respir Rev. 2016 Sep;25(141):278-86
pubmed: 27581827
Eur Clin Respir J. 2019 Dec 17;7(1):1702618
pubmed: 32002175
Thorax. 2010 Oct;65(10):921-6
pubmed: 20861296
Sarcoidosis Vasc Diffuse Lung Dis. 2012 Oct;29(2):113-8
pubmed: 23461073
Respirology. 2017 Jul;22(5):950-956
pubmed: 28166611
Respir Res. 2019 Oct 24;20(1):231
pubmed: 31651324
Respir Res. 2020 Jan 30;21(1):36
pubmed: 32000772
N Engl J Med. 2014 May 29;370(22):2083-92
pubmed: 24836312
Thorax. 2021 Jan;76(1):37-43
pubmed: 33023996
Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40
pubmed: 20935110
BMC Pulm Med. 2020 Jul 11;20(1):188
pubmed: 32652979
Lancet Respir Med. 2017 Dec;5(12):968-980
pubmed: 29033267
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Respir Res. 2017 Jan 17;18(1):18
pubmed: 28095852
Respir Med. 2010 Feb;104(2):296-304
pubmed: 19815403
Respir Res. 2017 Jul 14;18(1):139
pubmed: 28709421
Ann Am Thorac Soc. 2020 Jun;17(6):699-705
pubmed: 32040340
BMJ Open Respir Res. 2014 Jan 03;1(1):e000007
pubmed: 25478168
Lancet. 2011 May 21;377(9779):1760-9
pubmed: 21571362
Eur Respir J. 2002 Mar;19(3):405-13
pubmed: 11936515
Respir Res. 2019 May 30;20(1):105
pubmed: 31142314
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Respir Res. 2019 Mar 15;20(1):59
pubmed: 30876420
Eur Respir J. 2016 May;47(5):1472-80
pubmed: 26846831
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9
pubmed: 21940789
BMJ Open Respir Res. 2018 Nov 21;5(1):e000331
pubmed: 30555708
Curr Opin Pulm Med. 2013 Sep;19(5):474-9
pubmed: 23851327
Adv Ther. 2020 Jul;37(7):3292-3298
pubmed: 32451950
Am J Respir Crit Care Med. 2011 May 1;183(9):1231-7
pubmed: 21131468
Eur Respir J. 2007 Jun;29(6):1256-76
pubmed: 17540788
QJM. 2018 Aug 1;111(8):531-539
pubmed: 29788503
PLoS One. 2017 Jan 18;12(1):e0166462
pubmed: 28099456
Respir Res. 2021 Feb 5;22(1):40
pubmed: 33546682
Eur Respir J. 2017 Jan 18;49(1):
pubmed: 28100551